Metformin protects from oxaliplatin induced peripheral neuropathy in rats.

Oxaliplatin is a commonly used drug to treat cancer, extending the rate of disease-free survival by 20% in colorectal cancer. However, oxaliplatin induces a disabling form of neuropathy resulting in more than 60% of patients having to reduce or discontinue oxaliplatin, negatively impacting their chance of survival. Oxaliplatin-induced neuropathies are accompanied by degeneration of sensory fibers in the epidermis and hyperexcitability of sensory neurons. These morphological and functional changes have been associated with sensory symptoms such as dysesthesia, paresthesia and mechanical and cold allodynia. Various strategies have been proposed to prevent or treat oxaliplatin-induced neuropathies without success. The anti-diabetic drug metformin has been recently shown to exert neuroprotection in other chemotherapy-induced neuropathies, so here we aimed to test if metformin can prevent the development of oxaliplatin-induced neuropathy in a rat model of this condition. Animals treated with oxaliplatin developed significant intraepidermal fiber degeneration, a mild gliosis in the spinal cord, and mechanical and cold hyperalgesia. The concomitant use of metformin prevented degeneration of intraepidermal fibers, gliosis, and the altered sensitivity. Our evidence further supports metformin as a new approach to prevent oxaliplatin-induced neuropathy with a potential important clinical impact.

Drosophila acetylcholinesterase: effect of post-translational [correction of post-traductional] modifications on the production in the baculovirus system and substrate metabolization.

Acetylcholinesterase cDNAs from Drosophila melanogaster modified on its primary sequence were cloned into baculovirus and were expressed in Sf9 cells with the aim to identify a mutant form that produces the enzyme at a high level. Directed mutagenesis was used in order to independently knockout different sites of post-translational modifications: exchange of the C-terminal hydrophobic peptide for a glycolipid molecule, dimerization by disulfide bridge, N-linked glycosylation at the five accessible sites, and subunit formation by proteolytic cleavage of a hydrophilic peptide found in the precursor. Another mutation involved the elimination of a free cysteine in the mature protein. All mutations involving post-translational modifications resulted in lower recoveries, suggesting that they are useful for maintaining high amounts of protein in the synapse. By contrast, elimination of a free cysteine in the mature protein permitted an increase in the level of production of the enzyme. These mutations did not affect specific activity of the enzyme at substrate concentrations ranging from 3 microM to 200 mM, suggesting that activation and inhibition of the enzyme activity does not originate from a polymorphism in post-translational modifications.